Lions Festivals Appoints Festival Director
Lions Festivals appointed Louise Benson as Festival Director of the newly launched Lions Health festival, which celebrates creative communications in healthcare and wellness, and of Eurobest, Europe’s leading annual awards and festival for creative excellence in communications.
Benson previously worked at The Guardian Edinburgh International Television Festival, where she held the position of Festival Director since February 2011. She was previously Media Events and Festival Director at Emap Communications. Louise will take on her new role in January 2014.
“Louise brings to the role vast experience, fantastic organizational and leadership skills and a great understanding of the importance of creativity, which are at the core of all our events,” says Philip Thomas, CEO of Lions Festivals. “We very much look forward to welcoming Louise to Lions Festivals to lead Lions Health, an important launch next June into a new sector, and to continue to grow and innovate Eurobest.”
Newly Established Pharma Appoints Industry Vet as CEO
Medac Pharma, Inc., a subsidiary of Medac GMBH, a global pharmaceutical company, appointed Terri Shoemaker as its new President and CEO. Shoemaker previously served as Vice President of Sales at InterMune, Inc. Prior to joining InterMune, she cofounded BioPharm Strategic Solutions. In 2002, Shoemaker joined Pharmion Corporation, serving as National Sales Director and then Senior Director U.S. Commercial Operations.
“With the experience and resources of our parent company,” says Shoemaker in her new role as President and CEO, “we’re well-positioned to bring clinically tested products to the U.S. that have the potential to improve quality of life for patients across multiple diseases.”
Jeffery Winton is the new Senior Vice President, Chief Communications Officer of Astellas US LLC. Astellas Pharma, Inc. is based in Tokyo, and Winton will be reporting to Astellas CEO, Masao Yoshida. Winton will hold responsibilities for corporate brand and reputation management in the Americas.
Boston Biomedical appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase III clinical trial for metastatic colorectal cancer. Andrews most recently served as Executive VP and COO at Incyte Corporation.
Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, appointed Michael Narachi as Chairman of the Board of Directors. Narachi currently serves as President and CEO of Orexigen Therapeutics, Inc. He has 29 years of biotechnology and pharmaceutical experience.
Johnson & Johnson
Johnson & Johnson announced that Mark B. McClellan, MD, PhD, former FDA Commissioner and Senior Fellow in Economic Studies at Brookins Institution, joined the Board of Directors. McClellan will serve on the Regulatory, Compliance & Government Affairs Committee and the Science, Technology & Sustainability Committee of the Board. During his time at the FDA, McClellan implemented the Critical Path Initiative, regulatory reforms aimed at modernizing pharma manufacturing.
Alfonso “Chito” Zulueta is now Senior Vice President and President of the Emerging Markets business of Eli Lilly and Company. Zulueta will replace Jacques Tapiero, who is retiring after 31 years with the company. Zulueta previously held the position of President and General Manager of Lilly Japan since 2008, and he will continue to lead the company in Asian, Latin American, Middle Eastern, African, Russian and Turkish markets.
Jacek Glinka, former CEO for the Polpharma Group, is now President of Mylan’s European business. Glinka will be reporting to Mylan’s Chief Operating Officer, Hal Korman. During his time at Polpharma, Glinka led the company to become the leader in the Polish market—and one of the fastest growing pharmaceutical companies in the region.
National Pharmaceutical Council
Current Senior Vice President of Managed Markets for Boehringer Ingelheim Pharmaceuticals, Jeff Huth, was elected Chairman of the Board of Directors for The National Pharmaceutical Council. Huth has served on the NPC Board since 2009 and has previously held the positions of Vice Chair and Treasurer.
Nonin Medical, Inc.
Nonin Medical, Inc., the inventor of finger pulse oximetry and a leader in noninvasive medical monitoring, appointed Richard J. Eagle as Vice President of Sales. Eagle has more than 30 years of experience involving class II and III medical devices for the acute, sub-acute and extended care markets. He will leverage his experience to grow Nonin’s revenues by addressing changes in the global sales environment, evaluating strategic partnerships, and refining competitive strategies.
PDI, Inc. appointed molecular diagnostics industry veteran John M. Climaco, JD, to its Board of Directors. Climaco currently serves as a director on the boards of DigiRad Corporation and Perma-Fix Environmental Services, Inc. Previously, he practiced corporate and tax law for six years with Fabian & Clendenin.
Securus Medical Group, Inc., a privately held medical device company, appointed Steven Girouard, PhD as President and CEO. This appointment was made after the announced closing of a $6.5 million series B financing lead by Securus. Previously, Girouard held leadership roles at Johnson & Johnson, Guidant Corporation and Cleveland Clinic.
Teva has announced that CEO Jeremy Levin will step down and will be replaced by Eyal Desheh on an interim basis. This news comes after earlier reports that Levin had considered resigning over creative differences with Chairman Philip Frost related to the implementation of the drug maker’s recent plan to cut 5,000 jobs. Desheh previously held a position at Teva as Chief Financial Officer. The company’s Board of Directors has begun the search for a permanent successor.
Varian Medical Systems, Inc.
Regina E. Dugan, PhD, Senior VP of Advanced Technology and Projects (ATAP) for Google’s Motorola Mobility LLC, has been appointed to the Varian Board of Directors. Dugan previously served as Director of the Defense Advanced Research Projects Agency. Varian manufactures medical devices and software for cancer treatment through radiotherapy.